

CITATION REPORT

List of articles citing

Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome

DOI: 10.1111/j.1464-410x.2005.05394.x
BJU International, 2005, 95, 751-6.

Source: <https://exaly.com/paper-pdf/38175202/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
400	[Treatment of locally advanced prostate cancer]. 2005 , 44, 1295-302		1
399	Radical Prostatectomy for Locally Advanced Prostate Cancer: Technical Aspects of Radical Prostatectomy. 2005 , 3, 90-97		27
398	Management strategies for locally advanced prostate cancer. 2006 , 23, 119-29		8
397	Increasing prostate specific antigen following radical prostatectomy and adjuvant hormonal therapy: doubling time predicts survival. 2006 , 175, 1684-90; discussion 1690		20
396	Management of locally advanced prostate cancer: past, present, future. 2006 , 176, S34-41		10
395	Metastatic prostate cancer-does treatment of the primary tumor matter?. 2006 , 176, 1292-8		37
394	Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer. 2006 , 176, 564-8		178
393	Initial therapy with radical prostatectomy for high risk localized prostate cancer. 2006 , 176, S27-9; discussion S25-6		6
392	Prognostic factors in prostate cancer. 2006 , 1, 4		56
391	Radical prostatectomy for locally advanced prostate cancer: results of a feasibility study (EORTC 30001). 2006 , 42, 1062-7		50
390	Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. 2006 , 67, 1253-6		70
389	Side-effects of treatments for locally advanced prostate cancer. <i>BJU International</i> , 2006 , 97, 22-8	5.6	21
388	Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma. <i>BJU International</i> , 2006 , 98, 335-40	5.6	39
387	Outcomes of locally advanced prostate cancer: a single institution study of 209 patients in Japan. 2006 , 8, 555-61		21
386	Surgery for locally advanced disease. 2006 , 4, 59-66		
385	Critical comparison of laparoscopic, robotic, and open radical prostatectomy: techniques, outcomes, and cost. 2006 , 7, 193-9		28
384	Surgery for locally advanced disease. 2006 , 7, 209-16		

383	MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. 2006 , 50, 738-48; discussion 748-9	142
382	Persistently high levels of immunosuppressive cytokines in patients after radical prostatectomy. 2006 , 9, 420-5	6
381	A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months. 2006 , 36, 789-93	86
380	Treatment of locally advanced prostate cancer--the case for radical prostatectomy. 2006 , 77, 193-9	12
379	Laparoscopic and robotic radical prostatectomy. 2006 , 6, 1003-11	9
378	Evolving treatment paradigms for locally advanced and metastatic prostate cancer. 2006 , 6, 1639-51	3
377	Prostate Cancer. 2007 ,	4
376	The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. 2007 , 6, 1455-60	90
375	Radical prostatectomy for clinical T3 disease: expanding indications while optimizing cancer control and quality of life. 2007 , 4, 451-4	2
374	Intermediate-term potency, continence, and survival outcomes of radical prostatectomy for clinically high-risk or locally advanced prostate cancer. 2007 , 69, 1170-5	115
373	Transrectal ultrasound in the staging of clinical T3a prostate cancer. 2007 , 33, 79-82	2
372	[Role of surgery in stade cT3-4 N0M0 prostate cancer]. 2007 , 11, 483-9	2
371	Surgery alone for advanced prostate cancer?. 2007 , 5, 157-169	1
370	[Radical prostatectomy: open, laparoscopic and robotic. Looking for a new gold standard?]. 2007 , 31, 316-27	2
369	Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. 2007 , 178, 493-9; discussion 499	165
368	[Current treatment in high risk and locally advanced prostate cancer]. 2007 , 31, 445-51	2
367	Development of Nomogram for Predicting Pathologic Outcome using Prostate-specific Antigen, Gleason Score, and the Percentage of Positive Core in the Clinically Confined Prostate Cancers, and Comparison with Nomogram using Existing Factors. 2007 , 48, 789	1
366	Radical prostatectomy for clinical stage T3a disease. 2007 , 109, 1273-8	119

365	An algorithm for managing the failure of external beam radiotherapy in prostate cancer. <i>BJU International</i> , 2007 , 100, 518-27	5.6	11
364	Patient selection determines the prostate cancer yield of dynamic contrast-enhanced magnetic resonance imaging-guided transrectal biopsies in a closed 3-Tesla scanner. <i>BJU International</i> , 2008 , 101, 181-5	5.6	27
363	Outcome of surgery for clinical unilateral T3a prostate cancer: a single-institution experience. 2007 , 51, 121-8; discussion 128-9		125
362	A pretreatment table for the prediction of final histopathology after radical prostatectomy in clinical unilateral T3a prostate cancer. 2007 , 51, 388-94; discussion 395-6		45
361	Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study. 2007 , 51, 922-9; discussion 929-30		52
360	Is surgery good for advanced localised prostate cancer? It's time to find out!. 2007 , 51, 873-5		6
359	Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. 2007 , 52, 1374-80		16
358	Outcome of prostate cancer patients with initial PSA > or =20 ng/ml undergoing radical prostatectomy. 2007 , 52, 1058-65		33
357	Editorial comment on: Outcome of prostate cancer patients with initial PSA > or =20 ng/ml undergoing radical prostatectomy. 2007 , 52, 1065-6		1
356	Optimal treatment of locally advanced prostate cancer. 2007 , 25, 169-76		18
355	(11)C-acetate PET in the early evaluation of prostate cancer recurrence. 2007 , 34, 185-96		119
354	Diagnostik und Therapie des PSA-Progresses nach lokaler Primärtherapie des Prostatakarzinoms. 2007 , 13, 718-725		2
353	Critical comparison of laparoscopic, robotic, and open radical prostatectomy: Techniques, outcomes, and cost. 2007 , 5, 61-67		
352	The spectrum of prostate cancer care: from curative intent to palliation. 2007 , 8, 245-52		4
351	Radical prostatectomy for high-risk prostate cancer. 2008 , 26, 219-24		22
350	[The role of surgery in locally advanced prostate cancer]. 2008 , 47, 1417-23		1
349	The spectrum of prostate cancer care: From curative intent to palliation. 2008 , 6, 56-63		
348	Role of radical prostatectomy in the treatment of high-risk prostate cancer. 2008 , 6, 107-114		1

347	Role of radical prostatectomy in the treatment of high-risk prostate cancer. 2008 , 9, 203-10		10
346	Advances in robotic prostatectomy. 2008 , 9, 250-6		2
345	Prostatakarzinom. 2008 , 14, 1087-1102		
344	Long-term outcomes of radical prostatectomy with multimodal adjuvant therapy in men with a preoperative serum prostate-specific antigen level > or =50 ng/mL. 2008 , 113, 1544-51		35
343	Counterpoint: High-risk prostate cancer: the case for combination brachytherapy and external beam irradiation. 2008 , 7, 280-2; discussion 283		1
342	Initial clinical experience with real-time transrectal ultrasonography-magnetic resonance imaging fusion-guided prostate biopsy. <i>BJU International</i> , 2008 , 101, 841-5	5.6	144
341	Localized prostate cancer: can we better define who is at risk of unfavourable outcome?. <i>BJU International</i> , 2008 , 101 Suppl 2, 5-10	5.6	87
340	EAU guidelines on prostate cancer. 2008 , 53, 68-80		848
339	An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer. 2008 , 53, 253-9		88
338	Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer. 2008 , 53, 1172-9		43
337	Adjuvant radiotherapy for patients with locally advanced prostate cancer--a new standard?. 2008 , 54, 528-42		32
336	[MRI and prostate cancer: a paradigm shift]. 2008 , 89, 1053-64		8
335	Can conception of prostate cancer stem cells influence treatment dedicated to patients with disseminated disease?. 2008 , 71, 694-9		4
334	Surgical management of high risk prostate cancer: the Mayo Clinic experience. 2008 , 26, 530-2		18
333	Estrategias terapéuticas del cáncer de próstata de estadio T3. 2008 , 40, 1-11		
332	A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies. 2008 , 88, 53-60		24
331	What is the Role of Surgery for Locally Advanced Disease?. 2008 , 7, 400-405		4
330	[Surgery of locally advanced prostate cancer]. 2008 , 18, 1031-7		2

329	[Pathological stage T3 prostate cancer after radical prostatectomy: a retrospective study of 246 cases]. 2008 , 18, 586-94	2
328	Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy. 2008 , 179, 1354-60; discussion 1360-1	178
327	Prostate cancer management Helping your patient choose what is best for him. 2008 , 50, 27-34	1
326	Stratégies de prise en charge du cancer de la prostate de stade T3. 2008 , 3, 1-10	
325	Stratégies de prise en charge du cancer de la prostate de stade T3. 2008 , 1, 1-10	1
324	Outcomes of Robotic Prostatectomy for Treating Clinically Advanced Prostate Cancer. 2008 , 49, 325	2
323	Telomerase RNA Expression and DNA Ploidy as Prognostic Markers of Prostate Carcinomas. 2009 , 95, 744-752	9
322	Comparison of Extraperitoneal and Transperitoneal Robot-Assisted Radical Prostatectomy in Prostate Cancer: A Single Surgeon's Experience. 2009 , 50, 251	6
321	Prostate. 2009 , 1121-1180	2
320	Outcomes of locally advanced (T3 or greater) prostate cancer in men undergoing robot-assisted laparoscopic prostatectomy. 2009 , 23, 1519-22	26
319	Additional therapy for high-risk prostate cancer treated with surgery: what is the evidence?. 2009 , 9, 939-51	6
318	Robotic radical prostatectomy for patients with locally advanced prostate cancer is feasible: results of a single-institution study. 2009 , 19, 329-32	51
317	Robotic-assisted laparoscopic prostatectomy. 2009 , 101, 1491-6	26
316	Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. 2009 , 13, 1449-58	59
315	Adjuvant therapy after radical prostatectomy: clinical considerations. 2009 , 18, 247-54	2
314	The clinical significance and therapeutic implications of extraprostatic invasion. 2009 , 18, 203-12	2
313	Correlations between age, Charlson score and outcome in clinical unilateral T3a prostate cancer. 2009 , 11, 131-7	6
312	Trends in radical prostatectomy. 2009 , 16, 151-60	9

311	The first 1000 cases of laparoscopic radical prostatectomy in the UK: evidence of multiple 'learning curves'. <i>BJU International</i> , 2009 , 103, 1224-30	5.6	58
310	Oncological control after radical prostatectomy in men with clinical T3 prostate cancer: a single-centre experience. <i>BJU International</i> , 2009 , 103, 1173-8; discussion 1178	5.6	37
309	Intraoperative radiotherapy during radical prostatectomy for intermediate-risk to locally advanced prostate cancer: treatment technique and evaluation of perioperative and functional outcome vs standard radical prostatectomy, in a matched-pair analysis. <i>BJU International</i> , 2009 , 104, 1624-30	5.6	13
308	Locally advanced prostate cancer: the role of surgical management. <i>BJU International</i> , 2009 , 104, 449-54	5.6	14
307	New opportunities in the management of prostate cancer-related bone complications. 2009 , 27, S1-S20		4
306	Urinary and sexual outcomes in long-term (5+ years) prostate cancer disease free survivors after radical prostatectomy. 2009 , 7, 94		47
305	[EAU guidelines on prostate cancer]. 2009 , 33, 113-26		45
304	Bilan d'extension du cancer prostatique : quelle IRM?. 2009 , 19, F114-F117		
303	[Oncologic and functional outcomes after radical prostatectomy in T3 prostate cancer]. 2009 , 19, 285-90		1
302	Management of High-Risk Localised Prostate Cancer. 2009 , 8, 439-447		1
301	High-risk localized prostate cancer: role of radical prostatectomy. 2010 , 20, 204-10		11
300	Progresión metastásica, mortalidad cáncer específica y necesidad de tratamientos de segunda línea en pacientes con cáncer de próstata de alto riesgo tratados inicialmente mediante prostatectomía radical. 2010 , 34, 610-617		8
299	[Pelvic lymphadenectomy and radical prostatectomy. Recommendations of the German S3 guideline]. 2010 , 49, 206-10		5
298	[Radiation therapy for prostate cancer in the new S3 guideline. Part 1: localized and locally advanced prostate cancer]. 2010 , 49, 211-5		2
297	[Node-positive prostate cancer. Value of radical prostatectomy]. 2010 , 49, 1266-73		
296	Reply from Authors re: Michael W. Kattan. Classification and Regression Trees Versus Nomograms: A Bone Scan Positivity Example. <i>Eur Urol</i> 2010;57:559-60. 2010 , 57, 560-561		
295	Defining and treating high-risk prostate cancer: can we do better?. 2010 , 58, 8-9		7
294	Radical retropubic prostatectomy for prostate cancer with microscopic bladder neck involvement: survival and prognostic implications. <i>BJU International</i> , 2010 , 105, 946-50	5.6	4

293	Prognostic factors for and outcome of locally advanced prostate cancer after radical prostatectomy. <i>BJU International</i> , 2010 , 105, 1536-40	5.6	17
292	Is radical prostatectomy a viable therapeutic option in clinically locally advanced (cT3) prostate cancer?. <i>BJU International</i> , 2010 , 106, 1596-600	5.6	18
291	Editorial comment from Dr Lallas to robotic-assisted laparoscopic radical prostatectomy: learning curve of first 100 cases. 2010 , 17, 640-1		0
290	Editorial comment from Dr Kadono to robotic-assisted laparoscopic radical prostatectomy: learning curve of first 100 cases. 2010 , 17, 641-2		0
289	Multimodal approaches to high-risk prostate cancer. 2010 , 17 Suppl 2, S33-7		11
288	Role of surgery in high-risk localized prostate cancer. 2010 , 17 Suppl 2, S25-32		22
287	Can we predict real T3 stage prostate cancer in patients with clinical T3 (cT3) disease before radical prostatectomy?. 2010 , 51, 700-7		9
286	Is radical prostatectomy the best option for localized prostate cancer? Current opinion and research. 2010 , 47		
285	Role of radical prostatectomy for high-risk prostate cancer. 2010 , 51, 589-95		2
284	Topographical sensitivity and specificity of endorectal coil magnetic resonance imaging for prostate cancer detection. 2010 , 84, 388-94		16
283	Radical prostatectomy for high-risk prostate cancer. 2010 , 40, 3-9		7
282	Outcomes of radical prostatectomy in clinically locally advanced N0M0 prostate cancer. 2010 , 85, 166-72		2
281	Oncologic outcome of robot-assisted laparoscopic prostatectomy in the high-risk setting. 2010 , 24, 1963-6		11
280	[Treatment of locally advanced prostatic cancer]. 2010 , 63, 689-95		2
279	Descending nerve-sparing radical prostatectomy--results and consequences. 2010 , 41 Suppl 1, S66-9		2
278	Clinical implications of changing definitions within the Gleason grading system. 2010 , 7, 136-42		35
277	[Recommendations Onco-Urology 2010: Prostate cancer]. 2010 , 20 Suppl 4, S217-51		45
276	Metastatic progression, cancer-specific mortality and need for secondary treatments in patients with clinically high-risk prostate cancer treated initially with radical prostatectomy. 2010 , 34, 610-617		

275	[Place of surgery in high-risk tumours of the prostate]. 2010 , 14, 493-9		2
274	Men's experiences of radical prostatectomy as treatment for prostate cancer. 2010 , 14, 125-33		29
273	Radical prostatectomy: does surgical technique influence margin control?. 2010 , 28, 219-25		14
272	What is the optimal management of high risk, clinically localized prostate cancer?. 2010 , 28, 557-67		17
271	Robotic radical prostatectomy in patients with high-risk disease: a review of short-term outcomes from a high-volume center. 2011 , 25, 455-7		51
270	[How to improve the surgery of prostate cancer?]. 2011 , 21 Suppl 1, S7-11		
269	[High-risk prostate cancer. Review by the Oncology Committee of the French Urology Association]. 2011 , 21, 901-8		2
268	EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease. 2011 , 35, 501-514		3
267	Role of radiation therapy for the treatment of lymph nodes in urologic malignancies. 2011 , 38, 497-506, vii		1
266	Men with organ-confined prostate cancer and positive surgical margins develop biochemical failure at a similar rate to men with extracapsular extension. 2011 , 78, 121-5		24
265	Avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment. 2011 , 77, 946-50		16
264	High-risk prostate cancer: the role of radical prostatectomy for local therapy. 2011 , 7, 543-50		4
263	Impact of adjuvant androgen deprivation therapy after radical prostatectomy on the survival of patients with pathological T3b prostate cancer. <i>BJU International</i> , 2011 , 107, 383-8	5.6	31
262	Pathological results and rates of treatment failure in high-risk prostate cancer patients after radical prostatectomy. <i>BJU International</i> , 2011 , 107, 765-770	5.6	99
261	Radical prostatectomy for cT3-4 disease: an evaluation of the pathological outcomes and patterns of care for adjuvant radiation in a national cohort. <i>BJU International</i> , 2011 , 108, 360-5	5.6	6
260	Inverse stage migration in patients undergoing radical prostatectomy: results of 8916 European patients treated within the last decade. <i>BJU International</i> , 2011 , 108, 1256-61	5.6	92
259	Incidence of lymphoceles after robot-assisted pelvic lymph node dissection. <i>BJU International</i> , 2011 , 108, 1185-90	5.6	78
258	EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. 2011 , 59, 61-71		1112

257	Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis. 2011 , 59, 832-40	141
256	Mortality among men with locally advanced prostate cancer managed with noncurative intent: a nationwide study in PCBaSe Sweden. 2011 , 60, 554-63	52
255	[EAU guidelines on prostate cancer. Part I: screening, diagnosis, and treatment of clinically localised disease]. 2011 , 35, 501-14	28
254	Long-term quality of life following primary treatment in men with clinical stage T3 prostate cancer. 2011 , 20, 111-8	7
253	Quality of life of patients after retropubic prostatectomy - pre- and postoperative scores of the EORTC QLQ-C30 and QLQ-PR25. 2011 , 9, 93	10
252	15 Role of radical prostatectomy in locally advanced prostate cancer. 2011 , 78, S11-S14	
251	Inaccuracies in assignment of clinical stage for localized prostate cancer. 2011 , 117, 283-9	50
250	Outcomes for patients with extraprostatic prostate cancer treated with trimodality therapy, including brachytherapy, external beam radiotherapy, and hormone therapy. 2011 , 10, 261-8	17
249	Neoadjuvant radiotherapy for locally advanced and high-risk prostate cancer. 2011 , 8, 107-13	23
248	Surgery for high-risk localized prostate cancer. 2011 , 3, 173-82	11
247	Biochemical recurrence after radical prostatectomy with or without pelvic lymphadenectomy in Korean men with high-risk prostate cancer. 2011 , 41, 656-62	13
246	Impact of clinical parameters on the diagnostic accuracy of endorectal coil MRI for the detection of prostate cancer. 2011 , 86, 393-8	7
245	Biomarker research in prostate cancer--towards utility, not futility. 2011 , 8, 131-8	31
244	Laparoscopic radical prostatectomy for locally advanced prostate cancer: our initial results. 2011 , 37, 14-19	
243	Radical prostatectomy in very high-risk localized prostate cancer: long-term outcomes and outcome predictors. 2012 , 46, 164-71	32
242	The importance of local control in high-risk locally advanced prostate cancer. 2012 , 19, S6-S12	6
241	Complications and functional results of surgery for locally advanced prostate cancer. 2012 , 2012, 706309	19
240	Oncologic outcomes of surgery in t3 prostate cancer: experience of a single tertiary center. 2012 , 2012, 164263	3

239 Cancer de la prostate: traitements. **2012**, 5, 1-19

238 20-Year survival after radical prostatectomy as initial treatment for cT3 prostate cancer. *BJU International*, **2012**, 110, 1709-13 5.6 55

237 Tratamiento del cáncer de próstata. **2012**, 44, 1-22

236 [pT3N0 prostate cancer treated with radical prostatectomy as sole treatment: Oncological results and predictive factors of recurrence]. **2012**, 22, 100-5 1

235 Ten-year follow-up of neoadjuvant therapy with goserelin acetate and flutamide before radical prostatectomy for clinical T3 and T4 prostate cancer: update on Southwest Oncology Group Study 9109. **2012**, 79, 633-7 28

234 The multi-disciplinary management of high-risk prostate cancer. **2012**, 30, 3-15 16

233 Tumor cytoreduction results in better response to androgen ablation--a preliminary report of palliative transurethral resection of the prostate in metastatic hormone sensitive prostate cancer. **2012**, 30, 145-9 37

232 Laparoscopic Radical Prostatectomy. **2012**, 1094-1118

231 Exclusive image guided IMRT vs. radical prostatectomy followed by postoperative IMRT for localized prostate cancer: a matched-pair analysis based on risk-groups. **2012**, 7, 158 6

230 Open Radical Prostatectomy. **2012**, 93-103 1

229 Controversies in the management of localized prostate cancer: radical prostatectomy still the standard of care. **2012**, 84 Suppl 1, e24-9 9

228 Radical prostatectomy as primary treatment of high-risk prostate cancer. **2012**, 13, 179-86 11

227 Comparative analysis of prostate-specific antigen free survival outcomes for patients with low, intermediate and high risk prostate cancer treatment by radical therapy. Results from the Prostate Cancer Results Study Group. *BJU International*, **2012**, 109 Suppl 1, 22-9 5.6 330

226 High-risk prostate cancer: from definition to contemporary management. **2012**, 61, 1096-106 101

225 Feasibility of minimally invasive radical prostatectomy in prostate cancer patients with high prostate-specific antigen: feasibility and 1-year outcomes. **2012**, 19, 923-7 0

224 Robotic radical prostatectomy as the initial step in multimodal therapy for men with high-risk localised prostate cancer: initial experience of 160 men. *BJU International*, **2012**, 109, 752-9 5.6 33

223 Locally advanced prostate cancer: a population-based study of treatment patterns. *BJU International*, **2012**, 109, 1309-14 5.6 34

222 The results of real-time brachytherapy for the management of low- and intermediate-risk prostate cancer in patients with prostate volumes up to 100 mL. *BJU International*, **2012**, 110, 383-90 5.6 11

221	Androgen deprivation therapy: past, present and future. <i>BJU International</i> , 2012 , 109 Suppl 6, 1-12	5.6	67
220	The role of surgery in high-risk localised prostate cancer. <i>BJU International</i> , 2012 , 110, E1-2	5.6	1
219	What is the best way to treat high-risk prostate cancer?. 2012 , 118, 12-4		1
218	Role of pelvic phased array magnetic resonance imaging in staging of prostate cancer specifically in patients diagnosed with clinically locally advanced tumours by digital rectal examination. 2013 , 31, 881-6		32
217	The predictive value of endorectal 3 Tesla multiparametric magnetic resonance imaging for extraprostatic extension in patients with low, intermediate and high risk prostate cancer. 2013 , 190, 1728-34		144
216	Radical prostatectomy in high-risk prostate cancer. 2013 , 20, 290-300		16
215	The heterogeneous Gleason 7 carcinoma of the prostate: analyses of low and high grade (risk) carcinomas with criteria of the International Society of Urological Pathology (ISUP). 2013 , 209, 190-4		7
214	DNA ploidy measured on archived pretreatment biopsy material may correlate with prostate-specific antigen recurrence after prostate brachytherapy. 2013 , 86, 829-34		8
213	Actualizaci3n de la estadificaci3n del c3ncer de pr3stata. 2013 , 77, 301-305		2
212	How can lymphocele development be prevented after laparoscopic radical prostatectomy?. 2013 , 27, 447-51		7
211	Accuracy of high resolution (1.5 tesla) pelvic phased array magnetic resonance imaging (MRI) in staging prostate cancer in candidates for radical prostatectomy: results from a prospective study. 2013 , 31, 448-54		33
210	Surgical management of prostate cancer. 2013 , 27, 1111-35, vii		6
209	Accurate patient selection and multimodal treatment offer the best therapeutic option in high-risk prostate cancer. 2013 , 13, 811-8		1
208	Prostate cancer: ESMO Consensus Conference Guidelines 2012. 2013 , 24, 1141-62		109
207	Robot assisted radical prostatectomy for elderly patients with high risk prostate cancer. 2013 , 31, 193-7		40
206	Locally advanced prostate cancer: current controversies and optimisation opportunities. 2013 , 25, 499-505		9
205	Lokal fortgeschrittenes Prostatakarzinom und lokales Rezidiv. 2013 , 19, 728-736		
204	Results of surgery for high-risk prostate cancer. 2013 , 23, 342-8		18

203	Robotic-assisted prostatectomy and open radical retropubic prostatectomy for locally-advanced prostate cancer: multi-institution comparison of oncologic outcomes. 2013 , 1, 31-6		21
202	The role of radical prostatectomy in high-risk prostate cancer. 2013 , 1, 95-101		17
201	The role of postoperative radiotherapy in prostate cancer patients. 2013 , 17, 413-20		
200	Epidural analgesia during open radical prostatectomy does not improve long-term cancer-related outcome: a retrospective study in patients with advanced prostate cancer. 2013 , 8, e72873		44
199	Radical prostatectomy for high-risk clinically localized prostate cancer: a prospective single institution series. 2013 , 5, 156		
198	Imaging. 2014 , 72-115		0
197	[Risk factors of recurrence after radical prostatectomy for locally advanced prostate cancer]. 2014 , 105, 91-6		
196	Cytoreductive prostatectomy: evidence in support of a new surgical paradigm (Review). 2014 , 45, 2193-8		12
195	Locally advanced and high risk prostate cancer: The best indication for initial radical prostatectomy?. 2014 , 1, 40-45		11
194	WITHDRAWN: Locally advanced and high risk prostate cancer: The best indication for initial radical prostatectomy?. 2014 ,		
193	The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer. 2014 , 120, 1656-62		21
192	Positive Surgical Margin Trends In Patients With Pathologic T3 Prostate Cancer Treated With Robot Assisted Radical Prostatectomy. 2014 , 150127063130004		1
191	Cryoablation for locally advanced clinical stage T3 prostate cancer: a report from the Cryo-On-Line Database (COLD) Registry. <i>BJU International</i> , 2014 , 113, 714-8	5.6	13
190	Prostate Cancer. 2014 , 19, 118-135		1
189	Prostate Cancer Grading. 2014 , 19, 108-117		
188	Current status of radical prostatectomy for high-risk prostate cancer. 2014 , 55, 629-35		9
187	Tailored treatment including radical prostatectomy and radiation therapy + androgen deprivation therapy versus exclusive radical prostatectomy in high-risk prostate cancer patients: results from a prospective study. 2014 , 40, 322-9		1
186	External validation of nomogram predicting the probability of specimen-confined disease (pT2-3a, RONO) in patients undergoing radical prostatectomy and pelvic lymph node dissection. 2014 , 93, 262-8		6

185	The status of surgery in the management of high-risk prostate cancer. 2014 , 11, 342-51		28
184	Long-term oncological outcome in men with T3 prostate cancer: radical prostatectomy versus external-beam radiation therapy at a single institution. 2014 , 19, 1085-91		25
183	Early salvage radiotherapy following radical prostatectomy. 2014 , 65, 1034-43		128
182	High-risk prostate cancer-classification and therapy. 2014 , 11, 308-23		215
181	The presence of extracapsular extension is associated with an increased risk of death from prostate cancer after radical prostatectomy for patients with seminal vesicle invasion and negative lymph nodes. 2014 , 32, 26.e1-7		45
180	Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis. <i>BJU International</i> , 2014 , 114, E62-E69	5.6	14
179	EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. 2014 , 65, 124-37		1360
178	Local treatment of high risk prostate cancer: Role of surgery and radiation therapy. 2014 , 120, 1608-10		4
177	[Neoadjuvant before surgery treatments: state of the art in prostate cancer]. 2014 , 24, 595-607		3
176	Prostate cancer: How to manage prostate cancer with lymph node metastases?. 2014 , 11, 137-8		1
175	Improving the surgical treatment of high-risk localised or locally advanced prostate cancer. 2015 , 6, 29-32		
174	The Value of Prognostic Grouping of Prostatic Carcinomas for Urologists and Pathologists. 2015 , 95, 436-44		3
173	A prospective study of nomogram-based adaptation of prostate radiotherapy target volumes. 2015 , 10, 243		7
172	Oncological outcomes of cryosurgery as primary treatment in T3 prostate cancer: experience of a single centre. <i>BJU International</i> , 2015 , 116, 79-84	5.6	10
171	Impact of laparoscopic radical prostatectomy on clinical T3 prostate cancer: experience of a single centre with long-term follow-up. <i>BJU International</i> , 2015 , 116, 102-8	5.6	7
170	What is the correct staging and treatment strategy for locally advanced prostate cancer extending to the bladder?. 2015 , 87, 130-5		2
169	Regional anaesthesia and analgesia: relationship to cancer recurrence and survival. 2015 , 115 Suppl 2, ii34-45		49
168	Surgery for high-risk prostate cancer and metastatic prostate cancer. 2015 , 39, 33-40		3

167	Primary radical therapy selection in high-risk non-metastatic prostate cancer. 2015 , 27, 136-44	6
166	Systematic review and meta-analysis of the survival outcomes of first-line treatment options in high-risk prostate cancer. 2015 , 5, 7713	29
165	Prostate cancer staging with extracapsular extension risk scoring using multiparametric MRI: a correlation with histopathology. 2015 , 25, 1776-85	61
164	[Long term biochemical recurrence free survival after radical prostatectomy for cancer: comparative analysis according to surgical approach and clinicopathological stage]. 2015 , 25, 157-68	1
163	Variation between specialist urologists in reporting extraprostatic extension after radical prostatectomy. 2015 , 68, 465-72	7
162	Radical Prostatectomy for Locally Advanced Prostate Cancer: Current Status. 2015 , 86, 10-5	19
161	Prognostic value of seminal vesicle involvement by prostate cancer in radical prostatectomy specimens. 2015 , 39, 144-153	
160	Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. 2015 , 33, 2143-50	159
159	Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis. 2015 , 20, 1018-25	13
158	Genome-wide detection of allelic genetic variation to predict advanced-stage prostate cancer after radical prostatectomy using an exome SNP chip. 2015 , 33, 385.e7-13	
157	Prognostic value of seminal vesicle involvement due to prostate cancer in radical prostatectomy specimens. 2015 , 39, 144-53	5
156	Positive Surgical Margin Trends in Patients with Pathologic T3 Prostate Cancer Treated with Robot-Assisted Radical Prostatectomy. 2015 , 29, 634-9	9
155	Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective. 2015 , 33, 235-44	21
154	Stratification of high-risk prostate cancer into prognostic categories: a European multi-institutional study. 2015 , 67, 157-164	133
153	Pretreatment tables predicting pathologic stage of locally advanced prostate cancer. 2015 , 67, 319-25	11
152	The accuracy of magnetic resonance imaging in prostate cancer staging: a single-institution experience. 2015 , 184, 313-7	7
151	Long-term outcomes of combined androgen blockade therapy in stage IV prostate cancer. 2015 , 141, 759-65	3
150	Clinically high-risk prostate cancer patients comprise a relevant number of cancers with overall favorable tumor characteristics. 2015 , 33, 85-92	2

149	Comparing conventional laparoscopic to robotic-assisted extended pelvic lymph node dissection in men with intermediate and high-risk prostate cancer: a matched-pair analysis. 2017 , 69, 101-107	3
148	Oncological outcomes following radical prostatectomy for patients with pT4 prostate cancer. 2016 , 42, 1091-1098	6
147	MR Spectroscopy in Prostate Cancer: New Algorithms to Optimize Metabolite Quantification. 2016 , 11, e0165730	6
146	Emerging minimally invasive procedures for focal treatment of organ-confined prostate cancer. 2016 , 32, 795-800	10
145	Robotic Surgery for cT3 prostate cancer. 2016 , 15, 35-35c	
144	Ten- and 15-yr Prostate Cancer-specific Mortality in Patients with Nonmetastatic Locally Advanced or Aggressive Intermediate Prostate Cancer, Randomized to Lifelong Endocrine Treatment Alone or Combined with Radiotherapy: Final Results of The Scandinavian Prostate Cancer Group-7. 2016 , 70, 684-691	48
143	High-risk prostate cancer: the role of surgical management. 2016 , 102, 135-43	10
142	Radioterapia externa en el tratamiento del cáncer de la próstata: experiencia personal 1993-2015. 2016 , 76, 298-310	
141	The role of radical prostatectomy as an initial approach in high-risk prostate cancer. 2016 , 40, 353-360	
140	Management of Locally Advanced (Nonmetastatic) Prostate Cancer. 2016 , 467-477	
139	National trends and differences in morbidity among surgical approaches for radical prostatectomy in Germany. 2016 , 34, 1515-1520	16
138	Treatment of the Primary Tumor in Metastatic Prostate Cancer: Current Concepts and Future Perspectives. 2016 , 69, 775-87	52
137	Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation. 2016 , 94, 254-62	24
136	Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. 2016 , 34, 57.e15-22	14
135	The role of radical prostatectomy as an initial approach for the treatment of high-risk prostate cancer. 2016 , 40, 353-60	2
134	Erectile Function Recovery after Radical Prostatectomy in Men with High Risk Features. 2016 , 196, 507-13	11
133	Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. 2016 , 34, 234.e13-9	13
132	The Significance of Accurate Determination of Gleason Score for Therapeutic Options and Prognosis of Prostate Cancer. 2016 , 22, 349-56	12

131	Prostate Cancer. 2016 , 1038-1095.e18	2
130	Accuracy of Magnetic Resonance Imaging for Local Staging of Prostate Cancer: A Diagnostic Meta-analysis. 2016 , 70, 233-45	324
129	Management of Prostate Cancer. 2017 ,	3
128	Radical Prostatectomy for Locally Advanced Prostate Cancers-Review of Literature. 2017 , 8, 175-180	4
127	Neoplasms of the Prostate. 2017 , 1-38	
126	Radical Prostatectomy for High-risk Localized or Node-Positive Prostate Cancer: Removing the Primary. 2017 , 18, 53	6
125	The clinical communication and information challenges associated with the psychosexual aspects of prostate cancer treatment. 2017 , 185, 17-26	16
124	Integration of MRI to clinical nomogram for predicting pathological stage before radical prostatectomy. 2017 , 35, 1409-1415	13
123	[Radical prostatectomy in locally advanced prostate cancer]. 2017 , 56, 1394-1401	6
122	Radical prostatectomy in oligometastatic prostate cancer. 2017 , 27, 572-579	7
121	New surgical approaches for clinically high-risk or metastatic prostate cancer. 2017 , 17, 1013-1031	5
120	The impact of multifocal perineural invasion on biochemical recurrence and timing of adjuvant androgen-deprivation therapy in high-risk prostate cancer following radical prostatectomy. 2017 , 77, 1279-1287	10
119	Post-prostatectomy Radiotherapy: Does "Salvage" Really Equal "Adjuvant"?. 2017 , 72, 710-711	
118	Approach to the Patient with High-Risk Prostate Cancer. 2017 , 44, 635-645	5
117	Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution. 2017 , 22, 1087-1093	10
116	Ga-PSMA PET/CT Imaging Predicting Intraprostatic Tumor Extent, Extracapsular Extension and Seminal Vesicle Invasion Prior to Radical Prostatectomy in Patients with Prostate Cancer. 2017 , 51, 314-322	29
115	Impact of lymphovascular invasion on lymph node metastasis for patients undergoing radical prostatectomy with negative resection margin. 2017 , 17, 321	11
114	American Brachytherapy Society Task Group Report: Combination of brachytherapy and external beam radiation for high-risk prostate cancer. 2017 , 16, 1-12	54

113	Adverse Features and Competing Risk Mortality in Patients With High-Risk Prostate Cancer. 2017 , 15, e239-e248	11
112	Increasing use of radical prostatectomy for locally advanced prostate cancer in the USA and Germany: a comparative population-based study. 2017 , 20, 61-66	22
111	Surgical Management of Localized and Locally Advanced Prostate Cancer. 2017 , 1-19	
110	Radical prostatectomy for locally advanced and metastatic prostate cancer. 2017 , 99, 259-264	14
109	It's all about the perspective: Removing bias when co-managing patients with high-grade T1 bladder cancer and localized prostate cancer-A competing risks analysis. 2018 , 36, 39-42	1
108	Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. 2018 , 36, 1399-1407	9
107	Neoadjuvant degarelix with or without apalutamide followed by radical prostatectomy for intermediate and high-risk prostate cancer: ARNEO, a randomized, double blind, placebo-controlled trial. 2018 , 18, 354	10
106	The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis. 2018 , 4, 369-375	8
105	PYGOPUS2 expression in prostatic adenocarcinoma is a potential risk stratification marker for PSA progression following radical prostatectomy. 2018 , 71, 402-411	5
104	Role of robot-assisted radical prostatectomy in locally advanced prostate cancer. 2018 , 25, 30-35	23
103	Laparoscopic Radical Prostatectomy. 2018 , 1140-1168	
102	Rolle der zytoreduktiven radikalen Prostatektomie beim oligometastasierten Patienten. 2018 , 25, 110-115	
101	Comparative effectiveness of radical prostatectomy with adjuvant radiotherapy versus radiotherapy plus androgen deprivation therapy for men with advanced prostate cancer. 2018 , 124, 4010-4022 ²⁸	
100	Robot-Assisted Radical Prostatectomy: A Prostate Surgeon's Perspective. 2018 , 463-470	
99	Influence of symptoms of depression on the quality of life of men diagnosed with prostate cancer. 2018 , 21, 70-78	1
98	Rolle der zytoreduktiven radikalen Prostatektomie beim oligometastasierten Patienten. 2018 , 20, 74-80	
97	Factors predicting biochemical recurrence after radical prostatectomy among patients with clinical T3 prostate cancer. 2018 , 48, 760-764	
96	Identifying the Best Candidate for Radical Prostatectomy in High-Risk Prostate Cancer. 2018 , 11-19	

95	Adjuvant Therapy in Locally Advanced Prostate Cancer. 2018 , 51-57		
94	Stage T3b prostate cancer diagnosed by seminal vesicle biopsy and treated with neoadjuvant hormone therapy, permanent brachytherapy and external beam radiotherapy. <i>BJU International</i> , 2019 , 123, 277-283	5.6	3
93	Lokale Therapie beim fortgeschrittenen und metastasierten Prostatakarzinom. 2019 , 23, 36-39		1
92	[Optimizing local control of high-risk prostate cancers through multimodal treatments]. 2019 , 29 Suppl 1, S8-S19		
91	Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017. <i>BJU International</i> , 2019 , 124, 373-382	5.6	7
90	Defining the incremental value of 3D T2-weighted imaging in the assessment of prostate cancer extracapsular extension. 2019 , 29, 5488-5497		19
89	Radikale Prostatektomie beim lokal fortgeschrittenen und metastasierten Prostatakarzinom. 2019 , 25, 315-321		
88	Management of Advanced and Metastatic Prostate Cancer: A Need for a Sub-Saharan Guideline. 2019 , 2019, 1785428		7
87	Comparing the Staging/Restaging Performance of 68Ga-Labeled Prostate-Specific Membrane Antigen and 18F-Choline PET/CT in Prostate Cancer: A Systematic Review and Meta-analysis. 2019 , 44, 365-376		11
86	Long-term outcomes in 1121 Australian prostate cancer patients treated with definitive radiotherapy. 2019 , 63, 116-123		2
85	Optimization of prostate cancer cell detection using multiplex tyramide signal amplification. 2019 , 120, 4804-4812		8
84	Definitive external-beam radiotherapy versus radical prostatectomy in clinically localized high-risk prostate cancer: a retrospective study. 2019 , 19, 3		4
83	Migration in last decade to high-risk prostate cancer after radical prostatectomy. 2019 , 29, 29-35		2
82	Prediction of organ-confined disease after robot-assisted radical prostatectomy in patients with clinically locally-advanced prostate cancer. 2019 , 42, 120-125		
81	Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for the Prediction of Extraprostatic Disease-A Risk Model for Patient-tailored Risk Stratification When Planning Radical Prostatectomy. 2020 , 6, 1205-1212		22
80	Neoplasms of the Prostate. 2020 , 415-525.e42		1
79	Perioperative mortality and morbidity of outpatient versus inpatient robot-assisted radical prostatectomy: A propensity matched analysis. 2020 , 38, 3.e1-3.e6		10
78	Primary Radical Prostatectomy or Ablative Radiotherapy as Protective Factors for Patients With mCRPC Treated With Radium-223 Dichloride: An Italian Multicenter Study. 2020 , 18, 185-191		6

77	Treatment gains from the "sandwich method" of abiraterone acetate for men with metastatic prostate cancer: a case report and sharing of our experience. 2020 , 9, 1448-1458	
76	Surgical management of high-risk, localized prostate cancer. 2020 , 17, 679-690	9
75	Surgery for pathological T3a, T3b and lymph node positive, prostate cancer: surgical, functional and oncological outcomes. 2020 , 205141582095820	
74	The significance of the visible tumor on preoperative magnetic resonance imaging in localized prostate cancer. 2021 , 9, 6-11	2
73	Role of laparoscopic radical prostatectomy in locally advanced and high-risk prostate cancer: Whether safe and effective approach?. 2021 , 4, 5	
72	The role of surgery in high risk and advanced prostate cancer: A narrative review. 2021 , 47, S56-S64	
71	Surgical treatment of patients with high-risk prostate cancer: long-term outcomes and prognostic factors. 2021 , 16, 99-111	2
70	The effect of risk factors on surgical and oncological results in high-risk prostate cancer: A multicentre study of the urooncology society, Turkey. 2021 , 75, e14281	
69	Tumour irradiation combined with vascular-targeted photodynamic therapy enhances antitumour effects in pre-clinical prostate cancer. 2021 , 125, 534-546	1
68	Das lokal fortgeschrittene Prostatakarzinom*. 2021 , 24, 42-50	
67	Prostate Brachytherapy: Low Dose Rate. 2013 , 719-738	1
66	Management of Localized and Locally Advanced Prostate Cancer. 2020 , 579-590	0
65	The role of hormonal treatment in prostate cancer. 2007 , 175, 211-37	16
64	Neoplasms of the prostate. 2008 , 442-579	3
63	Basic Terms and Concepts of Radiation. 2010 , 159-175	2
62	Perioperative complications of radical retropubic prostatectomy in patients with locally advanced prostate cancer: a comparison with clinically localized prostate cancer. 2013 , 15, 241-5	6
61	Role of Surgery in locally advanced prostate cancer. 2015 , 31, 710-6	8
60	Percutaneous prostate cryoablation as treatment for high-risk prostate cancer. 2007 , 62, 109-12	8

59	Treatment of patients with prostate cancer at high risk of its progression. 2019 , 8, 460	2
58	Prostatectomy Provides Better Symptom-Free Survival Than Radiotherapy Among Patients With High-Risk or Locally Advanced Prostate Cancer After Neoadjuvant Hormonal Therapy. 2018 , 16, 126-134	1
57	Multiparametric MRI - local staging of prostate cancer and beyond. 2019 , 53, 159-170	28
56	Quantitative Pathology: Historical Background, Clinical Research and Application of Nuclear Morphometry and DNA Image Cytometry. 2006 , 1, 126-139	2
55	RARP in high-risk prostate cancer: use of multi-parametric MRI and nerve sparing techniques. 2014 , 16, 715-9	7
54	Estrogen receptor (ER) but not androgen receptor expression is correlated with recurrence, progression and survival in post prostatectomy T3N0M0 locally advanced prostate cancer in an urban Greek population. 2015 , 17, 98-105	11
53	The association between metabolic syndrome and advanced prostate cancer in Chinese patients receiving radical prostatectomy. 2015 , 17, 839-44	12
52	Pathological outcomes and biochemical recurrence-free survival after radical prostatectomy for high-risk prostate cancer in the Indian population. 2018 , 34, 260-267	7
51	Comparison of Open versus Robotic Radical Prostatectomy in Clinically Advanced Prostate Cancer. 2008 , 49, 886	4
50	Outcome of surgery in locally advanced pT3a prostate cancer. 2011 , 64, 209-12	6
49	Radical prostatectomy for high-risk clinically localized prostate cancer: a prospective single institution series. 2011 , 5, E156-61	7
48	DNA-cytometric grading of prostate cancer Systematic review with descriptive data analysis. 2014 , 2, 7	7
47	Quantitative pathology: historical background, clinical research and application of nuclear morphometry and DNA image cytometry. 2006 , 1, 126-39	1
46	[Incidence of pelvic lymph node metastasis in radical prostatectomy]. 2006 , 63, 1011-4	
45	Efficacy of Radical Retropubic Prostatectomy as the Primary Treatment for Patients with Clinically Localized Prostate Cancer and a Serum PSA Level \leq 10 ng/ml. 2007 , 48, 945	
44	Indications for radical prostatectomy. 2007 , 23-37	
43	Les traitements du cancer localis� de la prostate. 2008 , 192, 1021-1026	
42	[Clinical study of radical prostatectomy for prostate cancer from a single institution]. 2009 , 100, 615-24	1

- 41 Outcome of Laparoscopic Radical Prostatectomy in High-Risk Prostate Cancer. **2009**, 50, 1101
- 40 Outcome of Radical Prostatectomy in Prostate Cancer Patients with Prostate-Specific Antigen (PSA) Level Equal to or More Than 20 ng/ml and No Distant Metastasis Preoperatively. **2009**, 50, 111 1
- 39 La chirurgie radicale pour cancer prostatique. **2011**, 159-172
- 38 Robot-Assisted Radical Prostatectomy: A Prostate Surgeon's Perspective. **2011**, 255-260
- 37 Treatment of Locally Advanced Prostate Cancer. **2012**, 2903-2920.e5 1
- 36 The Role for Radical Prostatectomy in Advanced Prostate Cancer. **2012**, 271-280
- 35 Prostate Cancer. **2012**, e51-1-e51-85
- 34 Management of Prostate Cancer: EAU Guidelines on Screening, Diagnosis and Treatment. **2012**, 299-326
- 33 Management of High-Risk/Locally Advanced Disease. **2013**, 831-842
- 32 Komplexe Fisteln der hinteren Harnröhre. **2014**, 1-18 1
- 31 Komplizierte Fisteln der hinteren Harnröhre. **2016**, 675-686
- 30 Rationale of Surgery in Locally Advanced and Oligometastatic Prostate Cancer. **2016**, 14, 97-108
- 29 Open Radical Prostatectomy. **2017**, 171-180
- 28 Prostate Cancer in Sub-Saharan Africa: Diagnosis and Management. **2017**, 95-107
- 27 ONCOLOGIC OUTCOMES OF RADICAL PROSTATECTOMY AND PROGNOSTIC STRATIFICATION IN PATIENTS WITH CLINICALLY LOCALLY ADVANCED PROSTATE CANCER. **2017**, 2, 30-37
- 26 Radical Prostatectomy in Locally Advanced Prostate Cancer. **2018**, 411-420
- 25 Failure of Ploidy and Proliferative Fraction to Predict Long-Term Outcome After Prostatectomy. **2018**, 9, 69-73
- 24 Prostate Gland Pathology. **2018**, 267-395

23 Surgical treatment in patients with localized and locally advanced prostate cancer: results of a monocentric study. **2018**, 7, 4 1

22 In Vivo Tracking of Mesenchymal Stem Cell in Rat Genitalia with Erectile Dysfunction Labeled by Superparamagnetic Iron Oxide Using Magnetic Resonance Imaging and Its Therapeutic Effect. **2018**, 15,

21 Extrafascial robot-assisted laparoscopic radical prostatectomy in locally advanced prostate cancer. **2019**, 74, 78-87 1

20 Surgical Management of Localized and Locally Advanced Prostate Cancer. **2019**, 191-209

19 Radical prostatectomy for high-risk prostate cancer | Opinion: NO. **2019**, 45, 428-434 2

18 Cancer care for patients with prostate cancer in the samara region depending on age and method of treatment. **2020**, 20, 119-124 0

17 Choices for surgery. **2007**, 175, 163-78

16 Pelvic Lymphadenectomy for Localized Prostate Cancer and Robotic-assisted Radical Prostatectomy. **2008**, 37-50

15 Tumor irradiation combined with vascular-targeted photodynamic therapy enhances anti-tumor effects in preclinical prostate cancer.

14 [Outcomes of radical prostatectomy in patients with prostate cancer at the Aristide Le Dantec University Hospital]. **2021**, 38, 56

13 Komplexe Fisteln der hinteren Harnröhre. **2022**, 1-13

12 Comparative oncological outcomes after radical prostatectomy or external beam radiation therapy plus androgen deprivation therapy in men with clinical T3b prostate cancer.. **2022**, 0

11 Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates.. **2022**, 0

10 Characteristics of Patients in SPCG-15A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer. **2022**, 41, 63-73

9 Is PSA Still the Best Predictor for Biochemical Recurrence after Radical Prostatectomy in High-Risk Prostate Cancer?. 1-6

8 Propensity score matching analysis comparing radical prostatectomy and radiotherapy with androgen deprivation therapy in locally advanced prostate cancer. **2022**, 12,

7 Nomograms and scoring system for forecasting overall and cancer-specific survival of patients with prostate cancer. 0

6 Safety and Efficacy Study of Neoadjuvant Radiohormonal Therapy for Oligometastatic Prostate Cancer: Protocol of an Open-Label, Dose-Escalation, Single-Centre Phase I/II Clinical Trial. **2022**, 29, 107327482211204 0

- 5 Indikationsstellung und Strategien beim Prostatakarzinom (PCa). **2022**, 1-8
- 4 Neoplasms of the Prostate. 1-46
- 3 Super-Extended Robot Assisted Radical Prostatectomy in Locally Advanced Prostate Cancer. **2022**, 351-358
- 2 Metabolic syndrome and its components predict the biochemical recurrence and adverse pathological features of patients following radical prostatectomy: a propensity score matching study. **2023**, 23,
- 1 Outcomes of radical prostatectomy in treatment of locally advanced prostate cancer: clinical observations. **2023**, 18, 42-55